Brian L. Hodous

发表

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones.

Stephanie D. Geuns-Meyer, H. Gunaydin, H. Nguyen, 2012, The Journal of organic chemistry.

Enantioselective Staudinger synthesis of beta-lactams catalyzed by a planar-chiral nucleophile.

G. C. Fu, Brian L. Hodous, 2002, Journal of the American Chemical Society.

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

T. Bush, Grace Chung, R. Radinsky, 2015, Journal of Medicinal Chemistry.

Catalytic asymmetric Staudinger reactions to form beta-lactams: an unanticipated dependence of diastereoselectivity on the choice of the nitrogen substituent.

Elaine C. Lee, G. C. Fu, Crystal Shih, 2005, Journal of the American Chemical Society.

Enantioselective addition of amines to ketenes catalyzed by a planar-chiral derivative of PPY: possible intervention of chiral Brønsted-acid catalysis.

G. C. Fu, Brian L. Hodous, 2002, Journal of the American Chemical Society.

Enantioselective Addition of Alcohols to Ketenes Catalyzed by a Planar-Chiral Azaferrocene: Catalytic Asymmetric Synthesis of Arylpropionic Acids

G. C. Fu, Brian L. Hodous, and J. Craig Ruble, 1999 .

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

M. Camps, A. Follis, B. Huck, 2019, Journal of medicinal chemistry.

Catalytic Asymmetric Staudinger Reactions to Form β-Lactams: An Unanticipated Dependence of Diastereoselectivity on the Choice of the Nitrogen Substituent.

Elaine C. Lee, G. C. Fu, Crystal Shih, 2005 .

1H‐Pyrrole‐2‐carbonitrile

Brian L. Hodous, P. Olivieri, 2009 .

Enantioselective Addition of Amines to Ketenes Catalyzed by a Planar-Chiral Derivative of PPY: Possible Intervention of Chiral Broensted-Acid Catalysis.

G. C. Fu, Brian L. Hodous, 2003 .

Enantioselective Addition of Alcohols to Ketenes Catalyzed by a Planar‐Chiral Azaferrocene: Catalytic Asymmetric Synthesis of Arylpropionic Acids.

G. C. Fu, J. C. Ruble, Brian L. Hodous, 1999 .

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

T. Bush, Marc Payton, Grace Chung, 2010, Cancer research.

N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.

P. Gallant, A. Cheng, J. Newcomb, 2008, Bioorganic & medicinal chemistry letters.

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

P. Gallant, M. Morrison, P. Rose, 2007, Bioorganic & medicinal chemistry letters.

Therapeutics , Targets , and Chemical Biology Preclinical Evaluation of AMG 900 , a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

T. Bush, Marc Payton, Grace Chung, 2010 .

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Nicolas Stransky, C. Lengauer, C. Winter, 2015, Cancer discovery.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Richard Kendall, P. Gallant, M. Morrison, 2007, Journal of medicinal chemistry.

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

Xin Huang, Christopher Mohr, Paul Hughes, 2009, Bioorganic & medicinal chemistry letters.

Targeting kinases with precision

A. Gardino, C. Lengauer, N. Brooijmans, 2018, Molecular & cellular oncology.

Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

A. Gardino, C. Lengauer, T. Guzi, 2015 .

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

David Powers, Paul Hughes, Richard Kendall, 2007, Journal of medicinal chemistry.

Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations

A. Gardino, C. Lengauer, N. Kohl, 2015 .

First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis

A. Gardino, C. Lengauer, T. Guzi, 2014 .